Drug intelligence / Profile preview

semdexa

Development stage: Phase 3
Lead developer: Scilex Holding
Modality: Hydrogel Systems → Drug Delivery Systems, Small Molecules
Administration: Epidural

Overview

Semdexa (SP-102) is a novel injectable corticosteroid gel formulation of dexamethasone sodium phosphate, developed for the treatment of moderate to severe lumbosacral radicular pain, commonly known as sciatica. It is administered epidurally and is preservative-free, surfactant-free, suspension-free, and particulate-free. Semdexa provides rapid onset of pain relief with effects lasting up to 99 days following a single injection. The drug has demonstrated statistically significant and clinically meaningful improvements in pain intensity and disability index scores in clinical trials[2][5][6].

Brand names: SEMDEXA™Semdexa
Other names: SP-102 (SEMDEXA™)

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on semdexa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on semdexa.

Explore the full profile